医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

交易中 05-27 09:42:03

912.854

-1.289

-0.14%

最高917.171	最低904.585	成交量309.87万
今开913.926	昨收914.143	日振幅1.38%
总市值0.00	流通市值0.00	总股本0.00
成交额4,583万	换手率--	流通股本0.00
市净率1.197822	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":912.85406,"timestamp":1779846122375,"preClose":914.143,"halted":0,"volume":3098730,"delay":0,"changeRate":-0.00141,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-1.28894,"latestTime":"05-27 09:42:03","open":913.92554,"high":917.1713,"low":904.58545,"amount":45834483,"amplitude":0.013768,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1779854400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1779845400000,1779854400000],[1779858000000,1779868800000]],"pbRate":1.197822,"peRate":10.781537,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2638245485","title":"复星医药子公司拟参投星曜坤泽，后者尚无产品上市，去年1至10月亏损1808万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638245485","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638245485?lang=zh_cn&edition=full","pubTime":"2026-05-27 08:52","pubTimestamp":1779843140,"startTime":"0","endTime":"0","summary":"5月26日晚间，复星医药（600196）发布公告称，公司控股子公司复星医药产业拟出资共计4.14亿元与其他新投资方共同参与星曜坤泽B轮融资并受让本公司联营公司苏州基金、天津基金所持有的星曜坤泽（下称“标的公司”）部分股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273750375029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0028","BK0060","BK1593","IPOS","BK0096","BK0175","02196","BK0188","BK0012","BK1515","BK0183","BK0196","BK0239","BK1191","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638438235","title":"复星医药（600196）披露对外投资暨关联交易公告，5月26日股价下跌0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638438235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638438235?lang=zh_cn&edition=full","pubTime":"2026-05-26 22:24","pubTimestamp":1779805464,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，复星医药报收于23.17元，较前一交易日下跌0.56%，最新总市值为618.74亿元。近日，复星医药发布《关于对外投资暨关联交易的公告》。公告显示，公司控股子公司复星医药产业拟出资41,437.50万元参与星曜坤泽B轮融资并受让苏州基金、天津基金所持股权，其中21,781.3912万元用于认缴新增注册资本，19,656.1088万元用于受让股权。交易完成后，预计持有星曜坤泽20.8709%股权。本次投资已获董事会审议通过，无需提交股东大会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600041243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0060","BK0028","BK0096","BK0012","600196","BK0183","BK0188","02196","BK0187","BK0175","BK0196","BK1191","BK1593","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251755","title":"三生制药(01530)拟委任毕马威为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251755","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638251755?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:01","pubTimestamp":1779800519,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药 发布公告，经考虑安永会计师事务所(安永)已担任本公司核数师逾15年，聘请具备同等资质的新核数师于未来数年为本公司及其附属公司进行审计工作将更加符合良好企业惯例。安永将于2026年股东周年大会结束时任期届满而煺任本公司核数师，且不会获续聘。鉴于毕马威上述品质，根据审计委员会的推荐，董事会认为建议委任毕马威为本公司核数师符合本公司及股东的整体利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1161","BK1583","HK0000165453.HKD","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638597731","title":"复星医药：控股子公司出资4.14亿元参与星曜坤泽B轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2638597731","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638597731?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:04","pubTimestamp":1779786240,"startTime":"0","endTime":"0","summary":"南财智讯5月26日电，复星医药公告，控股子公司上海复星医药产业发展有限公司拟出资共计人民币41437.50万元，其中21781.39万元用于认缴苏州星曜坤泽生物医药股份有限公司新增注册资本293.68万元，19656.11万元用于受让苏州基金及天津基金合计持有的星曜坤泽存续注册资本308.65万元；交易完成后，复星医药产业预计将持有星曜坤泽20.87%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605263749758734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0028","BK0060","BK1593","BK0096","BK0175","02196","BK0188","BK0012","BK1515","BK0183","BK0196","BK0239","BK1191","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638594329","title":"中缅边境瑞丽口岸今年以来出入境旅客突破200万人次","url":"https://stock-news.laohu8.com/highlight/detail?id=2638594329","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638594329?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:29","pubTimestamp":1779780540,"startTime":"0","endTime":"0","summary":"转自：中国新闻网中缅边境瑞丽口岸今年以来出入境旅客突破200万人次 　　　中新社云南德宏5月26日电 瑞丽出入境边防检查站26日通报，截至当日零时，中缅边境瑞丽口岸今年以来出入境旅客已突破200万人次，较2025年提前11天达成这一数据。今年以来，该口岸日均通关量超1.3万人次，单日最高为1.5万人次。　　今年以来，经瑞丽口岸出入境旅客主要以跨境贸易、探亲访友、观光旅游为主，缅甸籍旅客占比超过96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-26/doc-inhzffss1521249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638568587","title":"康哲药业(00867)：创新药高选择性TYK2抑制剂CMS-D001获得溃疡性结肠炎适应症和克罗恩病适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2638568587","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638568587?lang=zh_cn&edition=full","pubTime":"2026-05-26 06:30","pubTimestamp":1779748246,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，于2026年5月22日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于5月25日收到药物临床试验批准通知书。NMPA同意本集团开展临床试验以评价CMS-D001治疗溃疡性结肠炎适应症和克罗恩病适应症的安全性和有效性。目前，CMS-D001健康受试者I期研究已完成，银屑病和特应性皮炎的Ⅱ期临床试验正在开展中，首例受试者已入组。CMS-D001未来还拟开发用于治疗系统性红斑狼疮等自身免疫病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0738911758.USD","SG9999015986.USD","IE00BMCWC346.EUR","00867","LU2346227817.USD","06978","LU0949170772.SGD","LU1894683348.USD","CMS","LU1003077747.HKD","IE00BYV24P56.USD","LU0661504455.SGD","BK4208","BK1161","SG9999015952.SGD","159992","BK1574","IE00BVYPNQ40.USD","LU1894683264.USD","LU2488822045.USD","IE00BVYPNP33.GBP","SG9999004220.SGD","BK4585","SG9999015945.SGD","BK1191","BK1593","IE00BGHQDM52.EUR","SG9999015978.USD","LU0545039389.USD","LU2637428348.USD","LU2500361329.USD","BK4588","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558557","title":"昊海生物科技(06826)：股东楼国梁累计减持77.47万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558557","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638558557?lang=zh_cn&edition=full","pubTime":"2026-05-25 20:36","pubTimestamp":1779712605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，公司于2026年5月25日收到楼国梁先生出具的《关于股份减持结果的告知函》，其本次股份减持计划时间区间届满。截至2026年5月25日，楼国梁先生已通过集中竞价的方式累计减持公司股份77.47万股，占目前公司总股本2.3亿股的0.3369%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","06826","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637733973","title":"每周股票复盘：复星医药（600196）多款新药获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637733973","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637733973?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:09","pubTimestamp":1779559752,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，复星医药报收于23.4元，较上周的24.13元下跌3.03%。复星医药控股子公司复宏汉霖自主研发的HLX3902注射液获澳大利亚人类研究伦理委员会批准，并完成澳大利亚药品管理局备案，允许在澳开展Ⅰ期临床试验，系该药品全球首次获得临床试验许可。复星医药控股子公司重庆药友制药有限责任公司获得国家药品监督管理局批准，其左氧氟沙星注射液正式获准上市。该药品已获中国临床试验批准及澳大利亚药品管理局备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","02196","BK0012","BK1593","BK0096","BK1515","BK0188","BK0183","BK0175","600196","BK0028","BK0239","BK0196","BK0187","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637329142","title":"时间定了！云南这条高速部分路段即将通车","url":"https://stock-news.laohu8.com/highlight/detail?id=2637329142","media":"云南发布","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637329142?lang=zh_cn&edition=full","pubTime":"2026-05-23 15:00","pubTimestamp":1779519600,"startTime":"0","endTime":"0","summary":"请过往车辆按交通标志和道路标线提示通行，并注意行车安全。特此公告云南德孟高速公路投资开发有限公司2026年5月22日来源：云南日报资料：云南省交通运输厅 临沧市委宣传部信息员：黄加江编辑：马正麟","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-05-23/doc-inhywkfp6949269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","BK1593","02135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637381906","title":"复星医药(02196)控股子公司就左氧氟沙星注射液的药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637381906","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637381906?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:50","pubTimestamp":1779357023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，上海复星医药(集团)股份有限公司控股子公司重庆药友制药有限责任公司就左氧氟沙星注射液的药品注册申请获国家药品监督管理局批准。截至2026年4月，本集团现阶段针对该药品的累计研发投入约为人民币194万元。根据IQVIACHPA最新数据，2025年，左氧氟沙星注射剂于中国境内的销售额约为人民币10.57亿元。该药品本次获批上市，将进一步丰富本集团产品线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0196","BK0012","BK0028","BK0187","02196","BK1593","BK0183","600196","BK0239","BK1191","BK1515","BK0175","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109022016","title":"复星医药左氧氟沙星注射剂新药注册申请获中国药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1109022016","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109022016?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:46","pubTimestamp":1779356798,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其提交的左氧氟沙星注射剂新药注册申请，已获得中国国家药品监督管理局的正式批准。这一进展标志着该产品在中国市场上市销售的关键监管障碍已被清除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02196","BK0096","600196","BK0175","BK0012","BK0060","BK0187","BK1515","BK1593","BK0196","BK0188","BK0028","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637386195","title":"复星医药(600196.SH)子公司HLX3902注射液获准于澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2637386195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637386195?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:47","pubTimestamp":1779353268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)自主研发的HLX3902注射液(即STEAP1xCD3xCD28三特异性抗体)用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的Ⅰ期临床试验方案获得相关人类研究伦理委员会的批准、并通过澳大利亚药品管理局(Therapeutic Goods Administration)备案，系该药品于全球范围内取得的首个临床试验许可。复宏汉霖拟于条件具备后于澳大利亚开展该药品的相关临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0187","BK0096","BK0196","BK0175","BK0188","BK1515","BK0239","BK0183","BK0028","BK1593","02196","600196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849445","title":"复星医药：截至2026年5月20日本集团无逾期担保事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849445","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636849445?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:54","pubTimestamp":1779274440,"startTime":"0","endTime":"0","summary":"5月20日，复星医药发布公告称，截至2026年5月20日，包括本次担保在内，本集团实际对外担保金额折合人民币约2，121，217万元，约占2025年12月31日本集团经审计的归属于上市公司股东净资产的43.52%；均为本公司与控股子公司/单位之间、控股子公司/单位之间发生的担保。截至2026年5月20日，本集团无逾期担保事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743672945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0175","BK0060","BK0012","02196","600196","BK0187","BK0239","BK1593","BK0096","BK0183","BK0196","BK1515","BK1191","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159897116","title":"四环医药于2026年5月18日以每股1.0685港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1159897116","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159897116?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:25","pubTimestamp":1779110749,"startTime":"0","endTime":"0","summary":"2026年5月18日，四环医药控股集团有限公司宣布，于当日以每股1.0685港元的价格，回购了1000万股公司股份。此次股份回购是公司资本管理策略的一部分，旨在优化股本结构，并可能向市场传递管理层对公司内在价值及未来前景抱有信心的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1515","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636211400","title":"四环医药(00460)5月18日斥资1068.5万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636211400","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636211400?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:55","pubTimestamp":1779098139,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月18日，该公司斥资1068.5万港元回购1000万股股份，每股回购价1.05-1.08港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00460","BK1515","BK1593","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","BK1161","01672","LU1969619763.USD","LU0348766576.USD","LU0348767384.USD","LU1961090484.USD","06855","159992","LU2328871848.SGD","LU0417516738.SGD","LU0348783233.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0634319403.HKD","LU2488822045.USD","SG9999014674.SGD","BK1141","02162","BK1593","09939","159938","LU0348735423.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2778985437.USD","LU2399975544.HKD","09926","BK1587","IE00B543WZ88.USD","LU0348827113.USD","LU2476274720.SGD","02268","BK1574","BK1600","LU0348784397.USD","BK1515","00460","02410","BK1583","LU1720050803.USD","BK1191","06978","LU1794554557.SGD","LU0348825331.USD","LU0417516902.SGD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636932470","title":"昊海生物科技于5月15日斥资78.8万港元回购3.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636932470","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636932470?lang=zh_cn&edition=full","pubTime":"2026-05-17 11:25","pubTimestamp":1778988300,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　昊海生物科技（06826）发布公告，于2026年5月15日斥资78.8万港元回购3.6万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-17/doc-inhyekzs1720476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","06826","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061617","title":"每周股票复盘：复星医药（600196）获阿尔茨海默病新药全球开发选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061617","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636061617?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:56","pubTimestamp":1778954171,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，复星医药报收于24.13元，较上周的24.82元下跌2.78%。本周，复星医药5月12日盘中最高价报25.62元。本周关注点来自公司公告汇总：复星医药产业获授AR1001分子用于治疗阿尔茨海默病的全球多中心III期临床试验后90天内独家选择权。来自公司公告汇总：复星医药控股子公司桃红四物汤颗粒注册申请获国家药监局受理。协议涉及选择权费6000万美元，后续首付款及里程碑付款最高达1.8亿美元，另按销售分成支付。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","02196","BK0028","BK1515","BK0175","BK0239","BK0183","BK0060","600196","BK0188","BK0196","BK1593","BK0096","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635208430","title":"复星医药：公司开展许可类交易遵循市场化规律","url":"https://stock-news.laohu8.com/highlight/detail?id=2635208430","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635208430?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:00","pubTimestamp":1778846400,"startTime":"0","endTime":"0","summary":"证券日报网讯5月15日，复星医药在互动平台回答投资者提问时表示，公司开展许可类交易遵循市场化规律，近年来开展的重大许可交易的对方均非大股东及其关联方。如后续涉及关联交易，公司会遵照相关法律法规及股票上市地监管要求，履行必要的前置评估/估值程序，根据《公司章程》提请相应的审批机构审议，并依照股票上市地规则进行相应披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739146511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","600196","BK0096","BK0196","02196","BK1515","BK0060","BK0183","BK1593","BK0012","BK1191","BK0187","BK0175","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083481","title":"复星医药：星曜坤泽系由公司联营公司复健资本旗下基金所孵化的企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083481","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635083481?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:12","pubTimestamp":1778839954,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：您好，尊敬的复兴医药董秘。我是复兴医药的一名普通投资者，请问贵公司与苏州星耀坤泽是否有关联？有的话占比多少？该公司现在101及102药物研发进展如何？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739069829.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739069829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK1593","02196","BK1191","BK0012","BK0096","BK0028","BK1515","600196","BK0188","BK0239","BK0196","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0436},{"period":"6month","weight":-0.0134},{"period":"1year","weight":0.0995},{"period":"ytd","weight":-0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}